• Blog
  • Age-Related Macular Degeneration Drug Market Forecast | 2023-28

    Age-Related Macular Degeneration Drug Market Forecast | 2023-28

    Age-Related Macular Degeneration Drug Market Forecast | 2023-28
    Report code - SR1031 Delivery - 2 Weeks
    Age-Related Macular Degeneration Drug Market, Dynamics, Trends, and Market Analysis
    See more...

    Market Insights

    The Global Age-Related Macular Degeneration Drug Market is estimated to grow from USD 11.66 billion in 2022 to USD 17.79 billion by 2028 at a CAGR of 7.19% during the forecast period.

    Wish to get a Free Sample? Register here.

    What is Age-related Macular Degeneration Drug?

    Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, the central part of the retina responsible for sharp central vision. While there is currently no cure for AMD, there are several drugs available for its treatment.

    One of the commonly used drugs for treating AMD is called anti-vascular endothelial growth factor (anti-VEGF) medication. These drugs work by inhibiting the growth of abnormal blood vessels in the retina, which are characteristic of the wet form of AMD. By blocking the action of VEGF, a protein that promotes the growth of new blood vessels, these medications help slow down the progression of the disease and prevent further vision loss.

    Global Age-Related Macular Degeneration Drug Report Overview

    Market Size in 2028

    USD 17.79 Billion

    Market Size in 2022

    USD 11.66Billion

    Market Growth (2023-2028)

    CAGR of 7.19%

    Base Year of Study

    2022

    Trend Period

    2017-2021

    Forecast Period

    2023-2028

    Market Dynamics

    The growth of the global age-related macular degeneration drug market is primarily driven by rising incidences of eye-related health issues, particularly among adults.

    • The growing aging populace is another factor fuelling product demand.
    • The increasing prevalence of chronic diseases such as obesity and high blood pressure can result in macular degeneration and thus, is likely to augment the market growth.
    • In addition to this, increasing demand for advanced age-related macular degeneration drugs is likely to create lucrative opportunities for the players operating in the global age-related macular degeneration drug market in the coming years.

    To get the full scope of the report, Click here.

    Key Players

    Key players operating in the age-related macular degeneration drug market are-

    • Bayer AG (Germany),
    • F. Hoffmann-La Roche AG (Switzerland),
    • Regeneron Pharmaceuticals, Inc. (The U.S),
    • Novartis International AG (Switzerland),
    • Bausch Health Companies Inc. (Canada),
    • Pfizer Inc. (The U.S),
    • Kubota Pharmaceutical (The U.S),
    • Ophthotech Corporation (The U.S),
    • GlaxoSmithKline PLC (UK),
    • Rxi Pharmaceuticals, Inc. (The U.S),
    • Alimera Sciences Inc. (The U.S),
    • Santen Pharmaceuticals Co. (Japan), and
    • Allergan, Inc. (Ireland).

    Segments' Analysis

    Age-Related Macular Degeneration Drug Market: Application Trends

    The age-related macular degeneration drug market has been bifurcated into hospitals & clinics, diagnostic centres, and academic research institutes.

    • The hospital & clinics segment accounted for the largest market with a share of more than 45% in 2022 and is projected to register significant growth during the review period.
    • The segment growth can be attributed to the presence of established infrastructure and skilled professional healthcare providers.

    Age-Related Macular Degeneration Drug Market: Regional Trends

    The market in North America accounted for the largest market with a share of more than 50% in 2022 and is projected to grow at a significant CAGR during the assessment period.

    • The regional growth can be attributed to expanding geriatric populace and presence of key market players such as Regeneron Pharmaceuticals, Inc. (The U.S), and Pfizer Inc. (The U.S).
    • The market in Asia-Pacific is expected to be driven by significant growth of the healthcare industry.

    Want to know which region offers the best growth opportunities? Register here.

    COVID-19 Impact 

    The covid-19 outbreak impacted the growth of the age-related macular degeneration drug market negatively. The spread of coronavirus led to the enforcement of lockdown to curb the spread of the virus. This led to travel restrictions and supply chain disruptions. In addition to this, patients postponed their appointments due to fear of infection and thus, affected the market growth.

    Target Audience

    Here is the list of the group of customers that the Age-related Macular Degeneration Drug market hopes to have the greatest opportunity to convert-

    • Age related macular degeneration drug distributors
    • Age related macular degeneration drug suppliers
    • Age related macular degeneration drug manufacturers
    • Logistics organizations
    • Government bodies

    Critical Questions Answered in the Report

    • What are the key trends in the global Age Related Macular Degeneration Drug market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global Age Related Macular Degeneration Drug market?
    • What are the key strategies adopted by the major vendors to lead in the global Age Related Macular Degeneration Drug market?
    • What is the market share of the top vendors?

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

    We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

    Report Features

    This report provides market intelligence most comprehensively. The age-related macular degeneration drug market report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market. 

    What Deliverables Will You Get in this Report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth Analysis of the Age-Related Macular Degeneration Drug Market

    How lucrative is the future?

    The market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional, and country-level historical data and forecasts

    Which are the most attractive market segments?

    Market segment analysis and forecast

    Which are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirement?

    10% free customization

    Customization Options

    Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, the central part of the retina responsible for sharp central vision. While there is currently no cure for AMD, there are several drugs available for its treatment. One of the commonly used drugs for treating AMD is called anti-vascular endothelial growth factor (anti-VEGF) medication. These drugs work by inhibiting the growth of abnormal blood vessels in the retina, which are characteristic of the wet form of AMD. By blocking the action of VEGF, a protein that promotes the growth of new blood vessels, these medications help slow down the progression of the disease and prevent further vision loss.

    North America accounted for the largest market share in 2022 and is projected to grow at a significant CAGR.

    The hospital & clinics segment is expected to witness a significant growth rate in the market in the coming years.

    The Age-Related Macular Degeneration Drug Market is estimated to grow from USD 11.66 billion in 2022 to USD 17.79 billion by 2028 at a CAGR of 7.19% during the forecast period.

    Rising incidences of eye-related health issues, growing aging populace, increasing prevalence of chronic diseases are the factors driving the growth pf age-related macular degeneration drug market.

    Age related macular degeneration drug distributors, Age related macular degeneration drug suppliers, Age related macular degeneration drug manufacturers, Logistics organizations, Government bodies are the target audience in the age-related macular degeneration drug market.